Introduction
The strongest prognostic factor for survival is whether the tumor can be completely resected.
The overall outlook is poor for most patients with bronchogenic carcinoma.
The percentage of patients who survive with lung cancer for one year is around 42%.
The overall 5-year survival rate is on the order of 10-20%. 5-year survival rate of patients with local disease is 50%; it is 20% for patients with regional disease. In stage I disease 5-year survival for squamous cell is up to 40% and for patients with adenocarcinoma it is up to 30%. The 5-year overall lung cancer survival rate has nearly doubled in the last 30 yearsdue to advances in combined-modality treatment
For the undifferentiated lesions 5 year survival is closer to 3%
Prognosis
The strongest prognostic factor for survival is whether the tumor can be completely resected. The most important prognostic indicator therefore is the extent of disease and lymph node involvement.
In general
The overall outlook is poor for most patients with bronchogenic carcinoma.
The percentage of patients who survive with lung cancer for one year is around 42%.
The overall 5-year survival rate is on the order of 10-20%. 5-year survival rate of patients
With localized Disease
The 5-year overall lung cancer survival rate has nearly doubled in the last 30 years due to advances in combined-modality treatment
In stage I disease 5-year survival for squamous cell is up to 40% and for patients with adenocarcinoma it is up to 30%.
With local disease 5 year survival for T1 and stage T2 is 75% and 67% respectively.
For Regional Disease
it is 20% for patients with regional disease. The estimated survival for patients with advanced NSLC with chemotherapy is 6-12 months which is only minimally better than with supportive care alone
For the undifferentiated lesions 5 year survival is closer to 3%